Market Research Logo

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016’, provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia
  • The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects
  • The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Neutropenia Overview
Therapeutics Development
Pipeline Products for Chemotherapy Induced Neutropenia - Overview
Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis
Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies
Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes
Chemotherapy Induced Neutropenia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Chemotherapy Induced Neutropenia - Products under Development by Companies
Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes
Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
Apotex Inc.
Biocon Limited
Biogenomics Limited
Bolder Biotechnology, Inc.
Cellerant Therapeutics, Inc.
Chong Kun Dang Pharmaceutical Corp.
Cinfa Biotech S.L.
Dr. Reddy's Laboratories Limited
Gene Techno Science Co., Ltd.
Generon (Shanghai) Corporation Ltd.
Genexine, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Myelo Therapeutics GmbH
Octapharma AG
Pfenex Inc.
Pfizer Inc.
Reliance Life Sciences Pvt. Ltd.
Richter Gedeon Nyrt.
Sandoz International GmbH
USV Limited
Chemotherapy Induced Neutropenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BBT-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBT-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBT-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eflapegrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXG-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSA-GCSF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myelo-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romyelocel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WBI-2100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Neutropenia - Dormant Projects
Chemotherapy Induced Neutropenia - Discontinued Products
Chemotherapy Induced Neutropenia - Product Development Milestones
Featured News & Press Releases
Jul 04, 2016: Cinfa Biotech announces positive top-line clinical data of pegfilgrastim biosimilar candidate B12019
Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
Dec 16, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer
Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco
Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm
May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia
Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia
Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China
May 10, 2011: Dr Reddy’s Launches Pegfilgrastim In India Under Brand Name Peg-grafeel
Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients
Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology
Nov 22, 2010: Generon Completes Dosing In Phase I Study Of F-627 In Australia
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants
Sep 09, 2010: Generon Submits Investigational New Drug Application For F-627 To SFDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2016
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Biocon Limited, H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech S.L., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co., Ltd., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Genexine, Inc., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016
Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H2 2016
Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Chemotherapy Induced Neutropenia - Dormant Projects, H2 2016
Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H2 2016
Chemotherapy Induced Neutropenia - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2016
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report